XRTX
No price yet
Announcements
Nothing here yet
Daily updates
- XORTX Therapeutics plans to submit a Health Canada CTA for XRx-026 (XORLO) for gout, supporting Canadian clinical development intended to advance a future FDA NDA. The company also reported increased interest from potential commercialization partners, but no agreements have been signed.Oct 10, 2026
- XORTX plans to file an IND for XRx-026 in Q4 2026, advancing its XORLO oxypurinol formulation into a two-stage clinical program designed to support a future NDA.Sep 19, 2026
FDA designations
Nothing here yet